NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW

NewAmsterdam Pharma Co N.V.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$20.47+0.64 (+3.23%)

Close on Oct 19, 2026

Market cap: $2.53B
P/E (TTM): –
Dividend yield: –

NewAmsterdam Pharma Co N.V. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation & Amortization	0.22	0.11	0.05	0.01	0.01
Stock-Based Compensation	59	34	25	4.12	1.24
Change in Accounts Payable	4.91	-13	5.07	4.81	6.56
Change in Unearned Revenue	-2.02	-3.95	-8.71	18	–
Operating Cash Flow	-148	-159	-141	11	-30
Capital Expenditures	-0.25	-0.67	-0.02	-0.22	-0.02
Purchase of Investments	-297	-62	–	–	–
Sale & Maturity of Investments	122	–	–	–	–
Investing Cash Flow	-175	-63	-0.02	-0.22	-0.02
Taxes Paid on Share-Based Awards	–	-0.99	–	–	–
Financing Cash Flow	30	660	8.91	392	85
Foreign Exchange Rate Adjustments	13	-6.80	5.05	5.25	-4.68
Free Cash Flow	-148	-159	-141	10	-30
Income Taxes Paid	–	0.00	0.03	–	–
Interest Paid	–	–	–	0.28	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3432.2%
Net margin: -3644.2%
Return on equity, FY2025: -28.3%

Financial strength

Current ratio: 9.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 581.2%

Valuation

P/E ratio: –
Price to sales: 354.64
Price to book: 4.00
Dividend yield: –